Pulmonary Medicine

Pulmonary Medicine is a fully open access respiratory journal published by Wiley, carrying original research and review articles on the prevention, diagnosis and management of lung disease together with the molecular genetics, pathophysiology and epidemiology behind it. Its 2025 Journal Impact Factor is 1.9, with a five-year figure of 2.6 and a rank of 73rd among 107 titles in the respiratory system category.《肺医学》（Pulmonary Medicine）是由 Wiley 出版的完全开放获取呼吸病学期刊，刊登肺部疾病预防、诊断与治疗方面的原创论文和综述，也收分子遗传学、病理生理学与流行病学内容。2025 年影响因子为 1.9，五年影响因子 2.6，在呼吸系统类目 107 种刊物中列第 73 位。

The title started in Cairo in 2010 under Hindawi and has since moved to Hoboken, and its volumes are numbered by calendar year, so a paper is located by a seven-digit article number rather than a page range.刊物 2010 年由 Hindawi 在开罗创办，其后迁至霍博肯，卷号按日历年编排，文章凭七位数字编号定位，不用起止页码。

Scope

• The aims name original research and review articles on the prevention, diagnosis and management of lung and related diseases, and the same paragraph invites contributions from pulmonology, respiratory medicine and thoracic surgery.宗旨写明收载肺部及相关疾病预防、诊断与治疗的原创论文与综述，同一段文字还点名邀约呼吸内科与胸外科的稿件。
• Lung function testing, respiratory care and treatment are listed alongside those clinical fields, which is why a physiological study of a breathing technique can sit next to a hospital case series.肺功能检测、呼吸照护与治疗同上述临床领域并列，呼吸训练技术的生理学研究因此能与医院病例系列相邻。
• Chronic obstructive pulmonary disease supplies the largest single block of recent papers, from treatment adherence in stable outpatients and the pathogens behind acute exacerbations to regulatory T cells, long-term oxygen and cognitive decline, and heated humidified high-flow air in chronic bronchitis.慢性阻塞性肺疾病占近年论文的最大一块，从稳定期门诊患者的治疗依从性与急性加重致病菌，到调节性 T 细胞、长期氧疗与认知下降，以及慢性支气管炎患者使用加温湿化高流量空气的研究。
• Tuberculosis appears in its drug-resistant form, with bedaquiline-containing regimens, rapid molecular diagnostics, the GenoType MTBDR line-probe assay, host polymorphism studies and imaging of smear-negative disease.结核以耐药形态进入版面，包括含贝达喹啉方案、快速分子诊断、GenoType MTBDR 线性探针检测、宿主多态性研究，以及涂阴患者的影像学分析。
• Bronchiectasis draws work on the neutrophil-to-lymphocyte ratio as a severity marker, on aetiology and quality of life in non-cystic-fibrosis cases, and on the determinants of the disease among patients attending a chest clinic in Ethiopia.支气管扩张方面有以中性粒细胞与淋巴细胞比值作严重度标志的研究，也有非囊性纤维化病例的病因与生活质量分析，还有埃塞俄比亚胸科门诊患者患病决定因素的调查。
• Pneumonia papers separate bacterial from viral causes in hospitalised adults and test machine-learning models for predicting intubation, while severe acute respiratory syndrome coronavirus 2 arrives through ACE2 expression, markers of severity and the weaning failure of ventilated patients.肺炎论文区分住院成人患者的细菌性与病毒性病因，并检验预测插管的机器学习模型，新型冠状病毒则经 ACE2 表达、严重度生物标志物与机械通气患者的撤机失败进入版面。
• Post-COVID conditions get a systematic review of dyspnoea and chronic fatigue and a study of cardiorespiratory fitness, psychological wellbeing and quality of life, topics that keep the journal tied to the aftermath of the pandemic.新冠后遗状态方面有呼吸困难与慢性疲劳的系统综述，也有心肺适能、心理状态与生活质量的研究，这些题目让刊物持续跟进大流行的后续影响。
• Sleep-disordered breathing is covered through home respiratory polygraphy in children with obesity, the cardiovascular burden of combined COPD and obstructive sleep apnoea, and the severity of COVID-19 among patients with sleep apnoea in Jordan.睡眠呼吸障碍经三条线呈现，肥胖儿童的家庭呼吸描记、慢性阻塞性肺疾病合并阻塞性睡眠呼吸暂停的心血管负担，以及约旦睡眠呼吸暂停患者感染新冠后的严重程度。
• Cystic fibrosis work runs from highly effective modulator therapy in patients carrying unusual variants in the Middle East to vancomycin monitoring during pulmonary exacerbations, and to patient views on digital tools for self-management.囊性纤维化研究从针对中东少见变异携带者的高效调节剂治疗，到肺部急性加重期的万古霉素监测，再到患者对数字化自我管理工具的看法。
• Pulmonary vascular disease is treated with an eye on altitude, including parenteral prostanoids in high-altitude group 1 pulmonary hypertension, exercise echocardiography for chronic thromboembolic disease and quantitative CT angiography parameters in acute embolism.肺血管病带有高原视角，包括高海拔第一大类肺动脉高压的肠外前列环素治疗、慢性血栓栓塞性肺病的运动超声心动图评估，以及急性栓塞的定量 CT 血管造影参数。
• The pleura and the chest wall appear through the diagnostic yield of malignant effusion sampling across primary and metastatic cancers and a case report on bilothorax, as well as the morphological diversity of thoracic amyloidosis and surgical stress measured by heart rate variability.胸膜与胸壁方面有恶性胸腔积液取样的诊断阳性率、胆汁胸个案报告，也有胸部淀粉样变的形态学分析，以及用心率变异性测量的手术应激。
• Interventional pulmonology and thoracic oncology share space, with therapeutic bronchoscopy in non-small cell lung cancer, endobronchial ultrasound-guided cryobiopsy, and a bibliometric and latent Dirichlet allocation analysis of artificial intelligence research in lung cancer.介入肺病学与胸部肿瘤共用版面，包括非小细胞肺癌的治疗性支气管镜、支气管内超声引导冷冻活检，以及用文献计量与潜在狄利克雷分配分析肺癌人工智能研究的论文。
• Transplant and interstitial disease meet in a study of adherence to the ISHLT referral protocol for idiopathic pulmonary fibrosis and in 1.1-millimetre cryobiopsy for acute rejection surveillance in lung recipients.移植与间质性肺病在一处相接，一篇考察特发性肺纤维化患者对国际心肺移植学会转诊规范的依从性，另一篇用 1.1 毫米冷冻活检监测肺移植受者的急性排斥。
• Diagnostic imaging and lung function carry a steady share, from convolutional neural networks reading chest radiographs and chest CT used as a prognostic tool in SARS-CoV-2 pneumonia to spirometric patterns across body mass index categories in Ghana.影像与肺功能占稳定份额，从卷积神经网络判读胸片、胸部 CT 用作新冠肺炎预后工具，到加纳不同体质指数人群的肺量计检查模式。
• Field studies from Africa and the Middle East sit beside South American case series and European clinical work, and that reach is a settled habit of the journal rather than an occasional exception.来自非洲与中东的现场研究、南美的病例系列同在目录里，同欧美的临床工作并列，地域分布之广已成刊物可见的常态。
• Research Article and Review Article are the two content types named in the journal's own metadata, and the 2026 volume adds an abstract supplement to the usual run of papers.刊物自身元数据标出的内容类型为研究论文与综述两种，2026 年卷则在常规论文之外另出一册摘要增刊。

History

• The first volume is dated 2010 and holds a single registered paper, 10.1155/2010/570679, and the flow that followed reached 45 items in 2011 and 88 in 2012.第 1 卷标注 2010 年，只收一篇登记论文，编号 10.1155/2010/570679，随后两年分别增至 45 篇与 88 篇。
• Hindawi Publishing Corporation set the journal up in Cairo as one of its open access titles, and the NLM catalogue still keeps that city as the earlier place of publication.Hindawi Publishing Corporation 在开罗创办此刊，属其开放获取系列，美国国家医学图书馆目录至今把该城记为旧出版地。
• Numbering was continuous from the start. There were no issues to speak of and no page ranges either, so a paper was addressed by the year and an article number inside the DOI.编号自始连续，没有可称的期号，也没有起止页码，文章靠 DOI 里的年份与文章号定位。
• Output fell after 2012, to 35 papers in 2013, 23 in 2014, 15 in 2015 and 14 in 2016, and then to five in 2017 and eight in 2018.2012 年之后载文量回落，2013 年 35 篇，2014 年 23 篇，2015 年 15 篇，2016 年 14 篇，2017 年降至 5 篇，2018 年为 8 篇。
• MEDLINE took the journal from 2014, PubMed has indexed it since 2010 and the volumes also appear as full text in PubMed Central, which is why the NLM record gives 2010 as the starting year.MEDLINE 从 2014 年起收录，PubMed 自 2010 年即有其记录，各卷全文另见 PubMed Central，国家医学图书馆目录因此把起始年写作 2010。
• The years 2019 to 2021 recovered to sixteen, eighteen and eighteen papers, 2022 and 2023 thinned to five and six, the smallest lists since 2017, and 2024 came back to eleven.2019 年至 2021 年回升到 16 篇、18 篇与 18 篇，2022 年与 2023 年缩至 5 篇与 6 篇，是 2017 年以来最短的目录，2024 年回到 11 篇。
• Wiley bought Hindawi in 2021 and the imprint followed. The catalogue entry, revised in May 2026, gives Hoboken, New Jersey, with Wiley as publisher from 2024, where it once gave Cairo.Wiley 于 2021 年收购 Hindawi，出版地随之迁移，2026 年 5 月修订的目录记录把 2024 年起的出版方写作 Wiley，出版地记为霍博肯，旧记录则把开罗列为出版地。
• The DOI pattern changed with the migration. Papers up to April 2024 still read 10.1155/2024/5520174, one 2024 item appears as 10.1155/pm/5911646, and every paper from 2025 onward carries the pm form.DOI 形制随迁移而变，2024 年 4 月以前的文章仍是 10.1155/2024/5520174 的样子，2024 年有一篇改为 10.1155/pm/5911646，2025 年以后一律用后者。
• The prefix itself stayed at 10.1155, so a reader following citations across the change sees one registrant and two numbering habits inside a single decade.前缀仍是 10.1155，读者跨过这道界线追引文，看到的是同一注册方在十年里换了一套编号习惯。
• Copyright lines in the 2026 papers name the authors first and add that Pulmonary Medicine is published by John Wiley and Sons, a form of words the Hindawi years did not use.2026 年论文的版权行先写作者，再注明本刊由 John Wiley and Sons 出版，Hindawi 时期没有这种写法。
• Volume numbers follow the calendar, so 2026 is volume 2026, and the publisher registers one issue object per year under identifiers such as 10.1155/pm.v2024.1.卷号跟随日历年，2026 年即第 2026 卷，出版方每年登记一个期对象，标识形如 10.1155/pm.v2024.1。
• The Journal Impact Factor moved from 2 in 2023 to 2.1 in 2024 and 1.9 in 2025, against a five-year figure of 2.6, 578 citations in the window, a cited half-life of 12.1 years and 13 citable items in the year.影响因子 2023 年为 2，2024 年 2.1，2025 年 1.9，五年影响因子 2.6，统计窗口内被引 578 次，引用半衰期 12.1 年，当年可引用论文 13 篇。
• The title sits in the Emerging Sources Citation Index rather than the Science Citation Index Expanded, ranked 73rd of 107 in respiratory system with a composite percentile of 32.2.刊物归入新兴来源引文索引而非科学引文索引扩展版，在呼吸系统类目 107 种中列第 73 位，综合百分位 32.2。
• A print number, 2090-1836, and an electronic number, 2090-1844, were issued together, and the library abbreviation settled as Pulm Med in the NLM catalogue.纸本刊号 2090-1836 与网络刊号 2090-1844 一并配发，图书馆用的缩写在国家医学图书馆目录里定为 Pulm Med。
• Gold open access has been the only route from the first volume, with no subscription edition behind a paywall, and the 2025 share is recorded at 100 per cent.金色开放获取自第 1 卷起就是唯一通路，背后没有订阅版，2025 年的占比记为 100%。
• The 2026 volume has already logged 26 records in PubMed against 13 for the whole of 2025, and it carries an abstract supplement beside the ordinary papers.2026 年卷在 PubMed 已登记 26 条记录，2025 年全年为 13 条，该卷另在常规论文之外附一册摘要增刊。

Editors

• Each published paper names the academic editor who handled it in a note on the first page, a habit that leaves the editorial chain visible even where the referee reports stay closed.每篇刊出的论文都在首页注明经手的学术编辑，编者链条因此可见，评审意见则始终不公开。
• Referee names do not appear anywhere in the published record, so the review is anonymised on the reviewers' side while the handling editor is identified.评审人姓名在公开记录里不出现，评审一端匿名，经手的编辑则具名。
• Dates are equally explicit. One 2026 paper was received on 30 December 2025, revised on 28 May 2026 and accepted on 12 August, a little over seven months end to end.日期同样明确，2026 年一篇论文于 2025 年 12 月 30 日收稿，2026 年 5 月 28 日修回，8 月 12 日录用，全程七个多月。
• Accepted work reaches PubMed Central quickly. That same paper was released there on 26 September 2026, six weeks after acceptance.录用稿件很快进入 PubMed Central，同一篇在 2026 年 9 月 26 日上线，距录用六周。
• The journal's own metadata uses two content types, Research Article and Review Article, and a submission is expected to fit one of them rather than arrive as an unclassified note.刊物元数据只标研究论文与综述两种内容类型，来稿须落入其中一类，不能以无类别的札记形式送审。
• Synthesis carries weight in the list. Of 346 PubMed records, twenty are Reviews, fifteen Systematic Reviews and nine Meta-Analyses, together about one record in eight.综合类稿件在目录里分量不轻，346 条 PubMed 记录中有 20 篇综述、15 篇系统综述与 9 篇荟萃分析，合计约每八条占一条。
• Trials get through as well, with eleven randomised controlled trials, eighteen observational studies and nine multicentre studies among the same records, while case reports stay rare at three.试验类同样通行，同一批记录里有 11 项随机对照试验、18 项观察性研究与 9 项多中心研究，个案报告很少，仅 3 篇。
• Corrections appear as separate items tied to the paper they repair, and two erratum notices are indexed in the same window.更正以独立条目刊出并与原文相互关联，同一统计窗口内索引到 2 条勘误。
• Copyright stays with the authors and the licence is Creative Commons Attribution 4.0, so a figure can be reused with credit and no permission request.版权留在作者手中，许可为知识共享署名 4.0 协议，图片注明出处即可再用，不必另行申请。
• Manuscripts move through the publisher's online system rather than by electronic mail, and the author guidelines sit beside the article list on the Wiley platform.稿件走出版方的在线系统而非电子邮件，作者指南列在 Wiley 平台的论文目录旁边。
• Editorial taste runs wide within respiratory medicine. A single-centre series from a teaching hospital, a physiological study of a breathing exercise and a deep-learning model for chest radiographs can share one volume without crowding each other out.编辑口味在呼吸病学内部铺得很开，教学医院单中心系列、呼吸训练的生理学研究与胸片深度学习模型可以同处一卷，不必彼此让路。